RE:RE:RE:Lot of potential hereI get that investors are pissed off about taking on debt to buy back preferred stock. It pisses me off too.
Investors are missing the option value of a TauRx IPO.
HMTM is oral with a benign safety profile that requires minimal testing and treatment monitoring designed for early intervention to modify the underlying disease process and slow progression of Alzheimer’s.
In other words this medication would likely be prescribed by GPs who have become comfortable with Cholinesterase Inhibitors (Aricept & Exelon) over last couple of decades.
A $15B USD TauRx IPO would get Dundee over $600M CAD, a $30B USD IPO would get $1.2B CAD and a $45B IPO would get $1.8B CAD.
Dundee currently has a market value of $80M.
The placebo arm of the study was not actually a placebo resulting in missed end point. Is this holding down Dundee?